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We reported the emergence of resistance to medical triazoles of Aspergillus fumigatus isolates from patients
with invasive aspergillosis. A dominant resistance mechanism was found, and we hypothesized that azole
resistance might develop through azole exposure in the environment rather than in azole-treated patients. We
investigated if A. fumigatus isolates resistant to medical triazoles are present in our environment by sampling
the hospital indoor environment and soil from the outdoor environment. Antifungal susceptibility, resistance
mechanisms, and genetic relatedness were compared with those of azole-resistant clinical isolates collected in
a previous study. Itraconazole-resistant A. fumigatus (five isolates) was cultured from the indoor hospital
environment as well as from soil obtained from flower beds in proximity to the hospital (six isolates) but never
from natural soil. Additional samples of commercial compost, leaves, and seeds obtained from a garden center
and a plant nursery were also positive (four isolates). Cross-resistance was observed for voriconazole, posacon-
azole, and the azole fungicides metconazole and tebuconazole. Molecular analysis showed the presence of the
dominant resistance mechanism, which was identical to that found in clinical isolates, in 13 of 15 environ-
mental isolates, and it showed that environmental and clinical isolates were genetically clustered apart from
nonresistant isolates. Patients with azole-resistant aspergillosis might have been colonized with azole-resistant
isolates from the environment.
Invasive aspergillosis is a fungal disease caused by Aspergillus
species that primarily affects immunocompromised patients,
such as those treated for hematological malignancy. Patients
may become infected by inhalation of ambient air that contains
fungal spores. The Aspergillus conidia can penetrate into the
alveoli and if not effectively removed, may germinate, prolif-
erate, and cause invasive aspergillosis. Mortality and morbidity
due to invasive aspergillosis remain a significant problem.
Triazoles, such as itraconazole (ITZ), voriconazole, and
posaconazole, are used increasingly in the management of
patients with this disease. Although the risk of resistance due
to the increased use of triazoles is considered low (11), we
recently observed ITZ resistance rapidly emerging in clinical
Aspergillus fumigatus isolates (19, 22, 24, 25). Azole resistance
was observed in up to 6% of patients in our hospital and in up
to 14.5% of isolates sent to our laboratory from other hospitals
in The Netherlands, which were obtained from patients with
aspergillus disease (19). Furthermore, azole resistance has
been reported in other European countries (3, 13, 19). The
ITZ-resistant isolates also showed significantly reduced sus-
ceptibility to the other mold-active medical triazoles voricon-
azole and posaconazole (19). A substitution of leucine for
histidine at codon 98 (L98H), combined with a 34-bp tandem
repeat (designated TR) in the promoter region of the cyp51A
gene (TR/L98H), which is the target for antifungal azoles, was
found in 94% of isolates (14, 19, 24).
Azole resistance can develop through the exposure of the
fungus to azole compounds, which may occur in azole-treated
patients or through the use of azole compounds in the envi-
ronment. The dominance of a single resistance mechanism is
difficult to explain by resistance development in individual
azole-treated patients, as one would expect multiple resistance
mechanisms to develop. Also, spread by person-to-person
transmission of any Aspergillus isolate is highly unlikely. As
inhalation of airborne aspergillus spores is the common route
of infection for aspergillus diseases, we hypothesized that the
dominance of a single resistance mechanism in clinical ITZ-
resistant isolates was more consistent with acquisition from a
common environmental source (19). If azole-resistant A. fu-
migatus is present in our environment, patients could inhale
resistant spores and subsequently develop azole-resistant dis-
ease. Indeed, azole-resistant aspergillosis was reported in
azole-naïve patients, indicating that resistance does not exclu-
sively develop during azole therapy (24).
Favorable conditions for resistance development are expo-
sure to azole compounds and the presence of reproducing
fungus (1). A. fumigatus is abundantly present in our environ-
ment as saprophytic, reproducing fungi, most notably in soil
and compost. Furthermore, azoles are commonly used for
plant protection as well as material preservation. Therefore, it
appears that resistance development in A. fumigatus is feasible
in the environment, and isolates that develop resistance to
fungicides might be cross-resistant to medical triazoles.
We investigated if A. fumigatus isolates that are present in
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our environment are resistant to medical triazoles and if they
are cross-resistant to azole fungicides. Furthermore, we char-
acterized the isolates by microsatellite typing in order to de-
termine if they were genetically related to clinical A. fumigatus
isolates previously obtained from patients cared for in our
University Medical Center.
MATERIALS AND METHODS
We searched our private fungus culture collection for A. fumigatus isolates that
had been cultured from the hospital indoor environment. Most indoor environ-
ment isolates were obtained from air sampling of patient rooms. These isolates
had been stored in 10% glycerol at 80°C. In addition, samples were collected
from soil sampled from the direct surroundings of the University Medical Cen-
ter, from soil obtained from plant nurseries and from leaves, seeds, and compost
obtained from a garden center. Environmental sampling was carried out in the
months of July and August of 2007.
To recover A. fumigatus isolates from the outdoor environment, 2 g of soil,
pulverized leaves, or pulverized seeds was dissolved in 8 ml 0.2 M NaCl–1%
Tween 20. From this suspension, 100 l was plated on Sabouraud dextrose agar,
and plates were supplemented with 4 mg/liter of ITZ and incubated at 37°C. For
each A. fumigatus isolate that grew on the ITZ-containing agar (an ITZ isolate),
an azole-susceptible A. fumigatus isolate (ITZ) that had been cultured from the
same environment (outdoor or indoor) was selected.
Isolates were tested for their antifungal susceptibility to ITZ, voriconazole,
posaconazole, amphotericin B, terbinafine, and caspofungin using the CLSI
M38-A broth microdilution reference method (15). In addition, the activity of
five azole fungicides, including cyproconazole, metconazole, thiabendazole,
tebuconazole, and penconazole, was determined using the same method.
Molecular methods were used for strain identification, determination of the
resistance mechanism, and for genotyping. For this, conidia from each strain
were inoculated into 15 ml of GYEP medium (2% glucose, 0.3% yeast extract,
1% peptone) and grown for 48 h at 37°C. Mycelial mats were recovered, dried,
and subjected to a DNA isolation protocol (20). In order to rule out any cryptic
species within Aspergillus section Fumigati, molecular identification was per-
formed by amplification of parts of the -tubulin gene and calmodulin gene (10,
12). DNA sequences were determined using a BigDye Terminator version 3.1
cycle sequencing kit (ABI) and an ABI 3100 DNA sequencer. Sequence align-
ments were performed using CLUSTAL-X, and the neighbor-joining method
was used for the phylogenetic analysis (16, 19). Sequences were compared with
those of Aspergillus fumigatus, Aspergillus lentulus, Aspergillus viridinutans, As-
pergillus brevipes, Aspergillus novofumigatus, Aspergillus fumigatiaffinis, and Neo-
sartorya species, all obtained from the CBS Fungal Biodiversity Centre, Utrecht,
The Netherlands. The full coding sequence of the cyp51A gene was determined
by PCR amplification and subsequent sequencing (9). For analysis, the cyp51A
sequence under accession number AF338659 in GenBank was used for compar-
ison to detect mutations.
Microsatellite genotyping was used to determine the genetic relatedness be-
tween the environmental isolates described for A. fumigatus with a short tandem
repeat A. fumigatus assay (8). From six loci, consisting of three tri- and three
tetranucleotide repeats, fragments were amplified by using fluorescently labeled
primers (8). The sizes of the fragments were determined by addition of the
GeneScan LIZ[500] marker and subsequent analysis of the fragments on the
Applied Biosystems 3730 DNA analyzer. Assignment of repeat numbers in each
marker was determined from the GeneScan data by using the Peak Scanner
version 1.0 software (Applied Biosystems). The repeat numbers of the environ-
mental isolates were compared to those of our previously analyzed collection of
32 ITZ and 32 ITZ clinical A. fumigatus isolates cultured between 2000 and
2007 (19). Allele-sharing distance matrices were generated from the tandem
repeat numbers and were used as input to the Neighbor program of the PHYLIP
version 3.6 software package to produce dendrograms (2, 19).
To test for significant differences between antifungal susceptibilities, the t test
was used on the natural logarithm of the MICs.
RESULTS
A total of 248 A. fumigatus isolates, cultured from the hos-
pital indoor environment, were present in our fungus culture
collection. These isolates had been cultured between 1995 and
2007, and five isolates grew on the ITZ-containing agar slants
(ITZ): three isolates from air sampling of patient rooms in
the hematology ward in 2002, 2003 and 2005 and two from
hospital water in 2007 (Table 1).
TABLE 1. Characteristics of 15 ITZ and 15 ITZ environmental A. fumigatus isolates
Category Isolateno. Source of isolate
Year of
isolation
MIC (mg/liter)a Cyp51A substitutionb
ITZ VCZ POS AMB TER CAS TR Codon98 Other(s)
ITZ V17-24 Air sample, patient room 2002 16 1 0.5 0.5 0.031 0.25  L98H S297T, F495I
V22-76 Air sample, patient room 2003 16 16 0.5 0.5 0.031 0.25  L98H
V37-56 Air sample, patient room 2005 16 2 0.5 1 0.125 0.25  L98H
V61-56 Water filter sample 2007 16 4 0.5 0.5 0.25 1  L98H
V61-57 Water filter sample 2007 16 4 0.5 0.5 0.063 0.5  L98H
V61-50 Soil 2007 16 4 0.5 0.5 0.25 32  L98H
V61-79 Soil 2007 16 8 0.5 1 0.016 0.5  L98H
V62-05 Soil 2007 16 8 0.5 0.5 0.125 0.25  L98H
V62-09 Soil 2007 16 4 0.5 1 0.063 1  L98H Q141H
V62-10 Soil 2007 16 4 0.25 1 0.125 0.5  L98H
V62-14 Soil 2007 16 4 0.25 1 0.063 1 
V62-48 Seeds 2007 16 4 0.5 0.5 0.25 1  L98H S52T
V62-63 Compost 2007 16 16 0.5 1 0.0031 0.5  L98H
V62-79 Soil 2007 16 0.5 0.25 0.5 0.5 0.5 
ITZ V04-22 Air sample, patient room 2000 0.25 0.5 0.063 1 0.063 0.5 
V22-74 Air sample, patient room 2003 0.25 0.5 0.031 1 0.063 0.5 
V22-80 Air sample, patient room 2003 0.25 0.5 0.031 1 0.5 0.5 
V57-35 Water filter sample 2007 0.25 0.5 0.031 1 0.063 0.5 
V57-53 Water filter sample 2007 0.25 0.5 0.063 0.5 0.016 0.5 
V62-04 Soil 2007 0.25 1 0.125 0.5 0.25 0.5 
V62-06 Soil 2007 1 4 0.25 1 0.5 0.5  F46Y, M172V, E427K
V62-07 Soil 2007 0.5 0.5 0.125 1 0.063 1 
V62-12 Soil 2007 0.5 4 0.25 1 0.031 1  F46Y, M172V, E427K
V62-13 Soil 2007 1 2 0.25 1 0.5 1 
V62-23 Soil 2007 0.25 1 0.063 1 0.25 0.5 
V63-01 Soil 2007 0.25 0.5 0.031 0.5 0.125 0.5 
V63-03 Soil 2007 0.25 1 0.063 1 0.063 0.5 
V63-04 Soil 2007 0.25 0.5 0.063 0.5 0.016 0.5 
V63-05 Soil 2007 0.5 4 0.25 0.5 0.5 0.5 
a VCZ, voriconazole; POS, posaconazole; AMB, amphotericin B; TER, terbinafine; CAS, caspofungin.
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A. fumigatus was also cultured from 49 of 79 outdoor envi-
ronmental samples. Culture of soil samples taken from the
direct proximity of the hospital showed the presence of ITZ
A. fumigatus isolates in six samples obtained from flower beds.
Cultures from natural soil were A. fumigatus positive, but these
were never ITZ resistant. Following this observation, we cul-
tured compost used in the flower beds as well as seeds, leaves,
and compost that we obtained from a garden center and from
a plant nursery, both located in towns other than the hospital.
ITZ isolates were recovered from seeds (one isolate), com-
post from the plant nursery (one isolate), and commercial
compost from the garden center (two isolates). Control isolates
(ITZ) were matched 1:1 to the environment from which an
ITZ isolate was cultured. All 15 ITZ isolates were con-
firmed to be highly resistant to ITZ (MIC of16 mg/liter) and
showed reduced susceptibility to voriconazole (median MIC of
4 mg/liter; range of 0.5 to 16 mg/liter) and posaconazole
(median MIC of 0.5 mg/liter; range of 0.25 to 1 mg/liter)
compared to the ITZ control isolates (P  0.005). The me-
dian MICs for ITZ isolates were 0.25 mg/liter for ITZ, 0.5
mg/liter for voriconazole, and 0.063 for posaconazole (Table
1). No significant differences in MICs were observed for am-
photericin B (P  0.285), terbinafine (P  0.909), and caspo-
fungin (P  0.610). Three fungicides, cyproconazole, thia-
bendazole, and penconazole, showed no in vitro activity
against the ITZ and ITZ A. fumigatus isolates (Fig. 1).
Metconazole and tebuconazole showed activity against ITZ
isolates, with median MICs of 0.25 mg/liter and 2 mg/liter,
respectively. These compounds were significantly less active
against ITZ isolates, with the median MIC shifting to 1 mg/
liter for metconazole and to 16 mg/liter for tebuconazole
(P  0.005) (Fig. 1).
Sequencing of the cyp51A gene showed the presence of two
alterations, a 34-bp tandem repeat in the promoter region
combined with the presence of a mutation that led to a sub-
stitution at codon 98 of leucine to histidine (TR/L98H), in 13
of 15 (86%) ITZ isolates, which was identical to the mecha-
nism previously observed with the majority of resistant clinical
isolates (19). No changes were found in the cyp51A gene of the
two other ITZ isolates, indicating another yet unknown
mechanism of resistance, and the TR/L98H alterations were
absent in all of the 15 matched ITZ control isolates.
All ITZ and ITZ isolates were identified as A. fumigatus
by sequence analysis of the -tubulin and calmodulin genes.
Microsatellite typing of six STR loci showed that all isolates
were genetically unique. Comparing the genetic relatedness by
generating dendrograms of the STR profiles showed that the
ITZ environmental isolates clustered apart from ITZ envi-
ronmental isolates. Furthermore, the ITZ environmental iso-
lates were found to cluster with the previously analyzed azole-
resistant clinical isolates. Likewise the ITZ environmental
isolates clustered together with the azole-susceptible clinical
isolates in the remaining clusters. Two out of the three azole-
resistant isolates without the dominant TR and L98H muta-
tions clustered in azole-susceptible clusters (Fig. 2) (19).
FIG. 1. In vitro activity of five azole fungicides against 15 ITZ-resistant (black bars) and 15 ITZ-susceptible (gray bars) A. fumigatus isolates.
The number of isolates is given on the y axis, and the MIC (mg/liter) on the x axis. Those isolates that were not inhibited by a concentration of
16 mg/liter were assigned to the 16 mg/liter category.
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DISCUSSION
Our study provides for the first time evidence that patients
with invasive aspergillosis due to azole-resistant A. fumigatus
might acquire the fungus from the environment. We were able
to culture A. fumigatus isolates, resistant to ITZ, from the
indoor environment as well as the outdoor environment, with
soil and air samples from patient rooms being positive. The
emergence of resistant isolates in the hospital environment
coincided with that observed with clinical isolates, i.e., after the
year 1999 (19). The majority of indoor and outdoor environ-
mental azole-resistant isolates exhibited a phenotype and
mechanism of resistance that were identical to the main type
found for resistant isolates recovered from clinical samples of
patients admitted to our hospital. Also, microsatellite typing of
the isolates showed that the environmental and clinical azole-
resistant isolates clustered together, indicating genetic related-
ness and possibly a common ancestor.
We used ITZ-containing Sabouraud agar to select for resis-
tant isolates, which possesses the theoretical risk of induction
of resistance in the A. fumigatus isolates due to exposure to
ITZ. However, we regard this as highly unlikely, as the incu-
bation (exposure) period was short, i.e., a maximum of 48 h,
and most resistant isolates contained two genomic changes,
both of which are required for the resistant phenotype (14).
We have never found either of these changes separately in
azole-susceptible isolates. In addition, we have performed in-
duction experiments with wild-type isolates by repeated expo-
sure to ITZ but thus far have been unsuccessful in inducing
laboratory mutants containing the TR/L98H resistance mech-
anism (unpublished observations), which is similar to the ex-
perience reported by others (7). Detection of resistance mech-
anisms directly with the original sample, i.e., soil or compost,
for instance, by a specifically designed PCR, would overcome a
selection step that involves exposure of the isolates to azole
compounds.
The dominance of a single resistance mechanism and the
genetic relatedness between clinical and environmental iso-
lates indicate that acquisition of azole-resistant isolates from
the environment is the most important infection route, more
important than the generally recognized mode of resistance
development during azole therapy of patients with aspergillus
disease. The presence of A. fumigatus resistant to medical
triazoles in our environment yields a major threat for immu-
nocompromised patients, as it is unclear if (further) spread of
resistant isolates can be prevented and alternative treatment
options are limited, especially for invasive disease that has
spread to the central nervous system (21).
An important question is how resistance to medical triazoles
arises in environmental isolates. Although our study does not
address this issue, we have previously suggested the use of
azole fungicides for plant protection and material preservation
as a possible cause (19, 24). Azoles are widely used preharvest
in grain-growing and grass-growing environments as well as
postharvest to prevent spoilage (11). Also, azoles are used for
preservation of materials, such as paints, coatings, and wall
paper pastes, and are routinely applied to mattresses in order
to prevent fungal growth. In the present study, the azole-
resistant A. fumigatus isolates that we cultured from the out-
door environment were found exclusively in soil from flower-
beds. In natural soil, A. fumigatus was recovered, but azole
resistance was never observed. Since the flowerbeds contained
both compost and cultivated plants, we went on to culture
seeds, leaves, and compost which we obtained from a plant
nursery and a garden center and which were also found to
contain azole-resistant isolates. Fungicides are used during the
production of plants, and residues might be present in organic
matter that is used for composting. Azole fungicides are rec-
ognized to have the potential to persist in soil (4, 5, 18), and
fungicide residues have been detected in compost (23). Fur-
thermore, resistance to azole fungicides has been reported for
numerous plant pathogenic molds, such as Mycosphaerella gra-
minicola (6). As A. fumigatus is a thermotolerant fungus and
readily grows in compost heaps, resistance to azole fungicides
might arise under these conditions. Stepwise increased expo-
sure of the maize pathogen Colletotrichum graminicola, a fun-
gus also capable of causing cutaneous mycosis and keratitis in
humans, to the fungicide tebuconazole showed loss of activity
by this triazole as well as by ITZ and voriconazole, indicating
that fungicides are capable of inducing resistance to medical
azoles (17).
If fungicides are responsible for the emergence of resistance
to medical triazoles in A. fumigatus, a resistance mechanism
would have developed that causes primarily resistance to the
fungicide. Resistance to other azole compounds, such as med-
ical triazoles, can be expected if these compounds share the
same target or have a similar molecule structure. The sus-
pected fungicide or group of fungicides will be active against
ITZ isolates but will exhibit reduced activity against ITZ
FIG. 2. Genotypic relatedness of clinical and environmental azole-
resistant A. fumigatus isolates. The figure shows genetic distances of 15
environmental ITZ-resistant A. fumigatus isolates (blue squares, filled), 15
environmental control A. fumigatus isolates (blue squares, open), 32 clin-
ical ITZ-resistant A. fumigatus isolates (red circles, filled), and 32 clinical
control A. fumigatus isolates (red circles, open). All resistant isolates were
found to have the L98H substitution and a tandem repeat in the promoter
region of the cyp51A gene, except for the underlined isolates.
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isolates. Among the five fungicides that we have investigated in
this study, three exhibited no activity, while two were active
against the ITZ isolates. Both of these, metconazole and
tebuconazole, were significantly less active against the ITZ
isolates, indicating that the TR/L98H substitution results in a
cross-resistant phenotype, which supports a possible role for
fungicides in resistance development. As azole fungicides have
been used for many decades, further studies are required to
understand their role in the emergence of resistance. It is
important to investigate the temporal relationship between the
year of introduction of fungicides and the presence of cross-
resistance with medical triazoles. This would require the test-
ing of all azole fungicides licensed for use in The Netherlands,
prior to the emergence of azole resistance in A. fumigatus in
the year 2000. Also, laboratory experiments that determine the
ability of azole fungicides to induce mutations in the cyp51A
gene, most notably the TR/L98H substitution, would prove
such a relationship.
We therefore believe that our findings could be explained by
a relationship between environmental azole use and develop-
ment of cross-resistance to medical triazoles. The intensive use
of triazole fungicides creates an environment that allows the
TR/L98H strains to survive in our environment. Spread of the
TR/L98H and possibly other azole resistance mechanisms can-
not be excluded. In addition to the abovementioned research
and international surveillance studies of clinical isolates, envi-
ronmental sampling is required in order to determine and
track the spread of azole resistance in the environment.
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